Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.56 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1124642 | 0.86 | KMT2A (0.65) | TP53USP2MAPK1RECQLHSD17B10 | |
| SCHEMBL442163 | 0.86 | KMT2A (0.65) | TP53USP2MAPK1RECQLHSD17B10 | |
| SCHEMBL4152079 | 0.85 | MAPT (0.52) | TP53USP2MAPK1RECQLHSD17B10 | |
| SCHEMBL6200113 | 0.84 | CCR6 (0.54) | TP53USP2MAPK1RECQLHSD17B10 | |
| SCHEMBL11249360 | 0.84 | MAPT (0.57) | TP53MAPK1HSD17B10MAPTKDM4E | |
| SCHEMBL1124253 | 0.83 | NR1H2 (0.68) | TP53USP2MAPK1RECQLHSD17B10 | |
| SCHEMBL8780458 | 0.83 | USP2 (0.47) | TP53USP2MAPK1RECQLHSD17B10 | |
| SCHEMBL7069485 | 0.83 | TP53 (0.59) | TP53USP2MAPK1RECQLHSD17B10 | |
| SCHEMBL9814048 | 0.83 | KMT2A (0.51) | TP53HSD17B10MAPTKDM4EKMT2A | |
| SCHEMBL1124932 | 0.82 | NR1H2 (0.68) | TP53USP2MAPK1RECQLHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2284157-A1 | Quinolines useful in treating cardiovascular disease | Wyeth (US) | 2011-02-16 | — | — | EP | disclosed |
| US-7576215-B2 | Quinolines and pharmaceutical compositions thereof | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1692111-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | Wyeth, A Corporation of the State of Delaware (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005058834-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | WYETH (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | MITSUI CHEMICALS, INC. (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1266888-A1 | QUINOLINE DERIVATIVES AND MEDICINAL USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2002-12-18 | — | — | EP | disclosed |
| US-4343804-A | 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds | A. H. ROBINS COMPANY, INC. (US) | 1982-08-10 | — | — | US | disclosed |
| US-4277607-A | Process for the preparation of 4-chloroquinolines | ROUSSEL UCLAF (FR) | 1981-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | PPARG, PPARD, PPARA | TP53 571/4885USP2 2191/4885MAPK1 1212/4885 |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | NR1H2, NR1H3, SREBF1 | TP53 4850/4885USP2 2597/4885MAPK1 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.